Ahmed Negida1,2,3, Hazem S Ghaith4,5, Salma Yousry Fala4,6, Hussien Ahmed4,7, Eshak I Bahbah4,8, Mahmoud Ahmed Ebada4,7, Mohamed Abd Elalem Aziz4,9. 1. Medical Research Group of Egypt, Cairo, Egypt. ahmed01251@medicine.zu.edu.eg. 2. Faculty of Medicine, School of Medicine, Zagazig University, Sharkia, Zagazig, 44523, Egypt. ahmed01251@medicine.zu.edu.eg. 3. School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK. ahmed01251@medicine.zu.edu.eg. 4. Medical Research Group of Egypt, Cairo, Egypt. 5. Faculty of Medicine, Al-Azhar University, Cairo, Egypt. 6. Faculty of Medicine, Suez Canal University, Ismailia, Egypt. 7. Faculty of Medicine, School of Medicine, Zagazig University, Sharkia, Zagazig, 44523, Egypt. 8. Faculty of Medicine, Al-Azhar University of Damietta, Damietta, Egypt. 9. Neuropsychiatry Department, Omr Shahin Mental Hospital, Cairo, Egypt.
Abstract
BACKGROUND: Mavoglurant (AFQ056), a selective metabotropic glutamate receptor 5 (mGluR5) inhibitor, was tested for t levodopa-induced dyskinesia (LID) in patients with Parkinson's Disease (PD). However, clinical trials showed inconsistent results regarding the efficacy of mavoglurant in treating LID in patients with Parkinson's disease (PD). METHODS: A computer literature search of PubMed, Scopus, Web of science, and Cochrane CENTRAL was conducted until March 2021. We selected relevant randomized controlled trials comparing mavoglurant to placebo. Study data were extracted and pooled as mean difference (MD) in the meta-analysis model. RESULTS: Six RCTs were included in this meta-analysis with a total of 485 patients. Mavoglurant was not significantly superior to placebo in terms of the "off-time" (MD -0.27 h, 95% CI -0.65 to 0.11), "on time" (MD 0.29 h, 95% CI -0.09 to 0.66), Lang-Fahn activities of daily living dyskinesia scale (MD -0.95, 95% CI -1.98 to 0.07), UPDRS-III (MD -0.51, 95% CI -1.66 to 0.65), or UPDRS-IV (MD -0.41, 95% CI -0.85 to 0.03). However, the pooled modified abnormal involuntary movement scale favored the mavoglurant group than the placebo group (MD -2.53, 95% CI -4.23 to -0.82). CONCLUSIONS: This meta-analysis provides level one evidence that mavoglurant is not effective in treating the LID in patients with PD.
BACKGROUND:Mavoglurant (AFQ056), a selective metabotropic glutamate receptor 5 (mGluR5) inhibitor, was tested for t levodopa-induced dyskinesia (LID) in patients with Parkinson's Disease (PD). However, clinical trials showed inconsistent results regarding the efficacy of mavoglurant in treating LID in patients with Parkinson's disease (PD). METHODS: A computer literature search of PubMed, Scopus, Web of science, and Cochrane CENTRAL was conducted until March 2021. We selected relevant randomized controlled trials comparing mavoglurant to placebo. Study data were extracted and pooled as mean difference (MD) in the meta-analysis model. RESULTS: Six RCTs were included in this meta-analysis with a total of 485 patients. Mavoglurant was not significantly superior to placebo in terms of the "off-time" (MD -0.27 h, 95% CI -0.65 to 0.11), "on time" (MD 0.29 h, 95% CI -0.09 to 0.66), Lang-Fahn activities of daily living dyskinesia scale (MD -0.95, 95% CI -1.98 to 0.07), UPDRS-III (MD -0.51, 95% CI -1.66 to 0.65), or UPDRS-IV (MD -0.41, 95% CI -0.85 to 0.03). However, the pooled modified abnormal involuntary movement scale favored the mavoglurant group than the placebo group (MD -2.53, 95% CI -4.23 to -0.82). CONCLUSIONS: This meta-analysis provides level one evidence that mavoglurant is not effective in treating the LID in patients with PD.
Authors: Daniela Berg; Jana Godau; Claudia Trenkwalder; Karla Eggert; Iiona Csoti; Alexander Storch; Heiko Huber; Monica Morelli-Canelo; Maria Stamelou; Vincent Ries; Martin Wolz; Christine Schneider; Thérèse Di Paolo; Fabrizio Gasparini; Sam Hariry; Marc Vandemeulebroecke; Walid Abi-Saab; Katy Cooke; Donald Johns; Baltazar Gomez-Mancilla Journal: Mov Disord Date: 2011-04-11 Impact factor: 10.338
Authors: Dmitry Petrov; Ignacio Pedros; Maria Luisa de Lemos; Mercè Pallàs; Anna Maria Canudas; Alberto Lazarowski; Carlos Beas-Zarate; Carme Auladell; Jaume Folch; Antoni Camins Journal: Expert Opin Investig Drugs Date: 2014-06-24 Impact factor: 6.206
Authors: G Arabia; M Zappia; D Bosco; L Crescibene; A Bagalà; L Bastone; M Caracciolo; M Scornaienghi; A Quattrone Journal: Neurol Sci Date: 2002-09 Impact factor: 3.307